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The independent prognostic signiﬁcance of isolated tumour cells in bone marrow is still a matter of debate. This study
evaluated the possible association of bone marrow micrometastases with tumour progression and prognosis in patients
affected by gastric cancer. Bone marrow aspirates from both iliac crests were obtained from 114 consecutive patients
operated on for gastric cancer. The specimens were stained with monoclonal antibody CAM 5.2 which reacts predominantly
with cytokeratin ﬁlaments 8 and 19. Among 114 cases analysed, 33 cases (29%) had cytokeratine-positive cells in the bone
marrow. There was no signiﬁcant relationship between the presence of bone marrow micrometastases and site, depth of
tumour invasion, lymph node metastases, presence of metastases. Patients with cytokeratine-positive cells had a trend towards
a diffuse type histology (P=0.06). Among the 88 curatively resected patients, median survivals were 40 months and 36 months
for cytokeratine-negative and cytokeratine-positive subsets respectively (P=0.9). Recurrence of the disease was observed in 39
cases (44.3%); 11 of 24 (45.8%) in the cytokeratine-positive subset and 28 of 64 (43.7%) in the cytokeratine-negative subset.
In conclusion in our experience the presence of cytokeratine-positive cells in the bone marrow of curatively resected gastric
cancer patients did not affect outcome and its independent prognostic signiﬁcance remains to be proven before its ofﬁcial
acceptance in the TNM classiﬁcation.
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The widely used TNM staging system has a high prognostic power,
but it cannot predict the outcome in individual patients. Despite
radical excision of the primary tumour, almost half the patients
with gastric cancer ultimately will die of recurrence. It is likely that
this group of patients is understaged probably because of the
presence of occult metastatic disease at the time of initial surgery
(Kell et al, 2000).
Since epithelial cells are not present in bone marrow under
normal conditions, identiﬁcation of tumour cells in the bone
marrow by means of immunocytochemistry has been proposed as
a method to detect systemic micrometastatic disease (Lindemann
et al, 1992; Harbeck et al, 1994).
Bone marrow micrometastases have been found in over one-
quarter of patients undergoing curative resection of gastrointestinal
cancer (O’Sullivan et al, 1995) and according to some authors they
affected prognosis (Schlimok et al, 1991; Jauch et al, 1996).
However the independent prognostic signiﬁcance of isolated
tumour cells in bone marrow is still a matter of debate and
remains to be substantiated (Funke and Schraut, 1998; Hermanek
et al, 1999).
This prospective study was aimed at evaluating the possible
association of bone marrow involvement with clinico-pathological
features and prognosis in gastric cancer patients.
MATERIALS AND METHODS
From October 1996 to June 2000, 114 consecutive patients who
were operated on for gastric cancer at the First Department of
General Surgery of the University of Verona (Italy) underwent
bone-marrow aspiration from both upper iliac crests before
removal of the primary tumour. The median age of the patients
was 67 years (range 27–87); the ratio of men to women was about
2 to 1 (73 men).
Tumours were staged according to the 1997 pathologic classiﬁ-
cations (pTNM) of the International Union Against Cancer
(Sobin and Wittekind, 1997) and the histological classiﬁcation
followed the criteria of Lauren.
In 92 cases there was pathological conﬁrmation of curative
resection (classiﬁed as R0), while residual tumour was present in
22 cases, either microscopic (R1) or macroscopic (R2). None of
the R0 patients received postoperative chemotherapy or radio-
therapy.
Follow-up
None of the patients was lost to follow-up which consisted of
physical examination, routine blood chemistry, tumour markers,
abdominal ultrasound (or computed tomography of the abdo-
men), chest X-ray at 6 months interval and yearly digestive
endoscopy; other investigations were performed at the physician’s
judgement. Recurrences were classiﬁed as haematogeneous and
intra-abdominal (peritoneal or locoregional), on the basis of
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tion.
The median follow-up for surviving patients was 30 months
(range 9–49). The 22 cases with R1/R2 resection and the four
patients who died postoperatively were excluded from the survival
analysis.
Examination of bone marrow
The preparation of the samples and the immunocytochemical
procedures were performed as previously described with some
modiﬁcations (Pelosi et al, 1999a). Brieﬂy, bone marrow aspirates
(4 to 6 ml each) were collected in heparinized syringes, diluted
with an equivalent volume of RPMI 1640 and sedimented onto a
Ficoll-Hypaque density-gradient. The mononuclear cell layer was
washed three times in RPMI 1640 and then resuspended at
1/10
6 cells ml
71. This cell suspension was cytospun (Cytospin 3;
Shandon Scientiﬁc, Cheshire UK) using Shandon Megafunnel
disposable sample chambers. Each slide was composed of a mono-
layered spot of 2.061.4 cm containing 3.5–5.0610
5 well-
preserved mononuclear cells. Slides were ﬁxed in pure acetone at
48C for 5 min and stored at 7208C in aluminium foil until using.
Cytospin slides were incubated in a moist chamber with mono-
clonal antibody CAM 5.2 (IgG2a, Bechton Dickinson, CA, USA)
which reacts predominantly with cytokeratin ﬁlaments 8 and 19.
The reaction was developed with a commercially available
immunostaining kit (EnVision AP – Dako) according to the
manufacturer’s instructions.
The speciﬁcity of each assay was veriﬁed by replacing the
primary antibody with unrelated mouse IgG in buffer at compar-
able dilution. Cytospins from ﬁne needle aspiration biopsy of
surgically excised primary gastric adenocarcinomas stained in
parallel were employed as external positive controls, and myeloid
cells of each bone marrow aspirate were used as internal negative
control. Finally, as a control group, bone marrow aspirates were
collected from 31 patients with a variety of non-malignant
diseases (ﬁve sigmoid diverticulitis, six benign haematologic
diseases, nine cholelithiasis, 11 abdominal aneurysm). In a set of
experiments we used bone marrow aspirates from unrelated,
non-malignant diseases artiﬁcially contaminated with a known
number of gastric cancer cells taken by ﬁne needle aspiration
biopsy from surgical specimens to determine the sensitivity of
our immunocytochemical method in the detection of cytokera-
tin-reactive tumour cells as previously reported in detail (Pelosi
et al, 1999b). These contamination tests showed that cytokera-
tin-positive cells were detected in expected quantities in all
mixtures up to the ﬁnal dilution of 1/10
6 bone marrow cells,
either sedimenting mononuclear cells or granulocytes (data not
shown).
At least four slides of bone marrow aspirate for each patient
were evaluated independently and blindly by two observers (F
Pasini and G Pelosi) without knowledge of patient’s identity or
clinical course of the disease. Specimens were considered as being
positive if strong labelling of the cell cytoplasm was seen and the
cell morphology was consistent with that of epithelial tumour cells
(Figure 1).
Statistical analysis
The intra- and interobserver reproducibility was evaluated by
analysis of variance and Spearman’s rank test respectively. Signiﬁ-
cance of differences between patients with cytokeratine-positive
cells and patients with cytokeratine-negative cells was assessed by
a chi-square test. Survival curves were computed according to
the Kaplan-Meyer method, and compared by the log-rank test.
End point was considered death from gastric cancer. Deaths from
different causes were considered as censored observations at the
time of death.
RESULTS
Tumour cells in bone marrow were highlighted by a strong cyto-
plasmic labelling and presented almost exclusively as individual
cells (94%); both individual and clustered tumour cells were gener-
ally larger than normal mononuclear cells.
Control experiments showed that normal bone marrow elements
on cytospin preparations of both clinical material and a control
group of non-cancer patients were negative for cytokeratins, with
the exception of a few plasma cells and megakaryocytes which were
however morphologically identiﬁable.
Among 114 cases analysed, 33 cases (29%) presented cytokera-
tine-positive (CK+) cells in the bone marrow. Of the 88 patients
evaluable for survival, 24 presented CK+ cells (27.3%). In this
subset, the median number of CK+ cells was 7 (range 1–36) per
10
6 bone marrow mononuclear cells.
Demographics and clinical characteristics of the cohort are
shown in Table 1. There was no signiﬁcant relationship between
the presence of bone marrow micrometastases and site, depth of
tumour invasion, lymph node metastases, presence of metastases.
Patients with CK+ cells had a trend towards a diffuse type histol-
ogy (40% vs 21.7% respectively; P=0.06).
Median survivals were 40 months and 36 months for CK- and
CK+ subsets respectively (P=0.9) (Figure 2). In the CK+ group
there was no correlation between survival and any cut-off value
of positive cells.
Among the 88 curatively resected patients, recurrence of the
disease was observed in 39 cases (44.3%); 11 of 24 (45.8%) in
the CK+ subset and 28 of 64 (43.7%) in the CK- subset. In parti-
cular haematogeneous metastases were not associated with the
presence of CK positive cells (Table 2).
DISCUSSION
The detection of the presence of epithelial cells in bone marrow has
been studied as a prognostic factor in many epithelial malignancies
such as breast (Braun et al, 2000), small- (Pasini et al, 1998; Pelosi
et al, 1999a) and non small-cell lung cancer (Passlick et al, 1999)
and oesophageal cancer (Thorban et al, 1996). Bone marrow
isolated tumour cells are also evident in many patients with gastric
cancer, but its prognostic signiﬁcance is still uncertain (Funke and
Schraut, 1998; Hermanek et al, 1999). This study was aimed at
quantifying the presence of bone marrow involvement and its









l Figure 1 Individual and clustered gastric cancer cells in the bone marrow
highlighted by strong labelling for cytokeratin in the cytoplasm and with a
cell morphology consistent with that of tumor cells. (APAAP method,
1000 x, oil immersion).
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present investigation found that CK+ cells were present in about
30% of the patients with gastric cancer; however percentages of
positivity up to 53% have also been reported (Table 3).
The studies addressing the correlation between the presence of
CK+ cells and the main clinicopathological factors in gastric cancer
have yielded conﬂicting results. While statistically signiﬁcant corre-
lations with undifferentiated histology and/or more advanced
depth of tumour invasion were found in some studies (Schlimok
et al, 1991; O’Sullivan et al, 1995; Maehara et al, 1996; Heiss et
al, 1997), in others (Funke et al, 1996; Jauch et al, 1996; Schott
et al, 1998; Bonavina et al, 2001), as well in ours, there was no
correlation.
Clinical outcome in gastric cancer has been reported to be
affected by the presence of bone marrow inﬁltration in two
studies (Schlimok et al, 1991; Jauch et al, 1996). While in the
report by Schlimok et al, 1991 only 38 R0 patients were evalu-
ated, in the recent study by Jauch et al, 1996, the survival was
analysed in 109 R0 patients. In the latter study, the detection
of more than three tumour cells in bone marrow was associated
with poorer survival particularly in N0 and T1/T2 subsets.
However at multivariate analysis including all conventional risk
factors, the presence of CK+ cells was not an independent prog-
nostic factor. In contrast with these results, the present study
based on 92 R0 gastric cancer patients, failed to show any asso-
ciation between presence of bone marrow CK+ cells and
clinicopathological factors or survival (median survival 36 and
40 months in CK positive and negative subsets respectively;
P=0.9). Furthermore, no cut-off value was found in relation to
survival among positive patients.
The inconsistency among the reports can be explained mainly by
two factors: the clinical behaviour of this type of tumour and some
problems related to immunocytochemical techniques.
From the clinical point of view, the pattern of recurrence is
by large intra-abdominal (peritoneal and locoregional) while
systemic metastases are less frequent. Also in our series the
pattern of recurrence was mainly peritoneal and locoregional,









Table 1 Main demographic and clinical characteristics of 114 cases with gastric cancer according
to the presence or absence of cytokeratine positive cells in the bone marrow
All patients Cytokeratin Cytokeratin
(n=114) positive (n=33) negative (n=81) P value
Sex (men/women) 73/41 20/13 (61/39%) 53/28 (65/35%) 0.8
Site
Upper third 35 11 (31.4) 24 (68.6) 0.9
Middle third 35 9 (25.7) 26 (74.3)
Lower third 44 13 (29.5) 31 (70.5)
Depth of tumour invasion
pT1 20 4 (20.0) 16 (80.0) 0.3
pT2 34 8 (23.5) 26 (76.5)
pT3 45 18 (40.0) 27 (60.0)
pT4 15 3 (20.0) 12 (80.0)
Node involvement
pN0 32 8 (25.0) 24 (75.0) 0.7
pN1 38 13 (34.2) 25 (65.8)
pN2 21 6 (28.6) 15 (71.4)
pN3 23 6 (26.1) 17 (73.9)
Metastases
M0 82 21 (25.6) 61 (74.4) 0.3
M1 32 12 (37.5) 20 (62.5)
Histology
Intestinal 69 15 (21.7) 54 (78.3) 0.06
Diffuse 45 18 (40.0) 27 (60.0)































Figure 2 Kaplan–Meier estimates of survival probability in 88 patients
affected by gastric cancer who underwent R0 resection, according to the
presence (circle line; n=24) or absence (square line; n=64) of cytokera-
tine-positive cells in the bone marrow.
Table 2 Pattern of recurrences in 39 of the 88 patients who underwent
R0 resection according to the presence of cytokeratin positive cells
Cytokeratin Cytokeratin
positive negative
n=24 (%) n=64 (%) Total
Haematogenous 4 (16.6) 9 (14.1) 13
Intra-abdominal 7 (29.1) 19 (29.7) 26
11 (45.8) 28 (43.7) 39 (44.3)
*Numbers are absolute frequency with row percentage in parentheses.
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the various types of recurrences (Table 2). Theoretically speaking
bone marrow contamination can be better associated with
systemic spread, rather than with locoregional failure; neverthe-
less both types of recurrence (intra-abdominal and
haematogenous) are probably different steps of a unique and
complex process and should therefore be somehow linked. In
gastric tumours the overexpression of the protease system, and
in particular that of the urokinase-type plasminogen activator
(uPA) system, might be associated with the ability of tumour
cells to degrade basement membranes, to invade the surrounding
matrix and then establish distant metastases. Accordingly, recent
studies have shown the correlation of the uPA system either with
the presence of CK+ cells in bone marrow (Heiss et al, 1997) or
with later relapses (Allgayer et al, 1997). On the other hand, it
should be born in mind that ICC could pick up cells which
are non-viable or which are simply in transit (Andreyev and
Cunningham, 1997; Kell et al, 2000). Therefore correlation
between the presence of bone marrow CK+ cells and clinical
outcome is not straightforward.
Also the different immunocytochemical procedures used in the
various studies might be a source of bias. Different patterns of
speciﬁcity and sensitivity among the various MoAbs used are
known to inﬂuence the tumour-cell detection (Borgen et al,
1998; Page et al, 1999). Due to these problems, also in gastric
cancer there was a wide range of positivity (from 25% to 53%).
For these reasons, we paid particular attention to methodolo-
gical problems. The magnitude of 10
6 mononuclear cells has
been shown to provide a higher probability of detecting even
one or two positive cells (Borgen et al, 1998; Funke and Schraut,
1998). Another aspect that might be a source of pitfalls is that
during the cytospin procedure there is a loss of mononuclear
cells and the number of cells rescued on the slides is lower than
that counted in the suspension before starting the procedure. We
actually counted at least 1610
6 mononuclear cells on the cytos-
pin slides. Moreover, we are conﬁdent not to have underscored
the number of CK+ cells, since in preliminary experiments on
artiﬁcially contaminated bone marrow specimens, we were able
to detect one CK+ tumour cell out of 10
6 mononuclear cells.
In addition, double sedimentation experiments performed on
the same samples of artiﬁcially contaminated bone marrow aspi-
rates conﬁrmed that all or almost all tumour cells ﬂoated in the
phase of mononuclear cells (data not shown). Therefore, even in
the presence of a minimal bone marrow contamination, it is
likely that no tumour cell was missed owing to the different cell
layer sedimented.
Another critical point is morphology. As already pointed out,
false positive immunocytochemical reactions have been demon-
strated between haematopoietic and tumour cells (Borgen et al,
1998). Bone marrow tumour cell contamination is still a grey area
and it is risky not to take cell morphology into account; experi-
enced observers are therefore necessary for the evaluation of
bone marrow cytospins.
The discrepancy in terms of prognostic value of the presence of
ITC between the two larger studies calls for a wide co-operation
among the researchers in order to establish a consensus laboratory
protocol, to verify the neoplastic nature, the biological behaviour
and the actual relevance of the isolated tumour cells in gastric
cancer.
In conclusion, in our experience the presence of cytokeratine
positive cells in the bone marrow of curatively resected gastric
cancer patients did not affect outcome and its independent prog-
nostic signiﬁcance remains to be proven before its ofﬁcial
acceptance in the TNM classiﬁcation.
REFERENCES
Allgayer H, Heiss MM, Riesenberg R, Grutzner KU, Tarabichi A, Babic R,
Schildberg FW (1997) Urokinase plasminogen activator receptor (uPA-
R): one potential characteristic of metastatic phenotypes in minimal resi-
dual tumor disease. Cancer Res 57: 1394–1399
Andreyev HJN, Cunningham D (1997) Micrometastases: are they clinically
signiﬁcant disease? Gut 40: 555–556
Bonavina L, Soligo D, Quirici N, Bossolasco P, Cesana B, Lambertenghi Deli-
liers G, Peracchia A (2001) Bone marrow-disseminated tumor cells in
patients with carcinoma of the esophagus or cardia. Surgery 129: 15–22
Borgen E, Beiske K, Trachsel S, Nesland JM, Kvalheim G, Herstad TK,
Schlichtimg E, Qvist H, Naume B (1998) Immunocytochemical detection
of isolated epithelial cells in bone marrow: non-speciﬁc staining and
contribution by plasma cells directly reactive to alkaline phosphatase. J
Pathol 185: 427–434
Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CRM, Gastroph S,
Wischnik A, Dimpﬂ T, Kindermann G, Riethmueller G, Schlimok G
(2000) Cytokeratine positive cells in the bone marrow and survival of









Table 3 Review of the main studies in the literature dealing with bone marrow micrometastasis in gastric cancer patients
No patients
No cells MoAbs % of
Correlations
Author year All R0 analysed used positivity Clinico-pathological Overall survival
Schlimok et al, 1991 97 38 1.5610
5 CK2 35.1 Histology; Yes
(34/97) pN
Juhl et al, 1994 36 NR 2.5610
5 KL1 25 No NR
(9/36)
Funke et al, 1996 102 NR 1610
6 CK2 44.1 No NR
(45/102)
Maehara et al, 1996 46 NR 6610
5 CK2 32.6 Histology; NR
CAM 5.2 (15/46) pT
Jauch et al, 1996 and Heiss et al, 1997 180 109 1610
6 CK2 53.0 Borrmann Yes
(95/180) pT
uPA
Schott et al, 1998 62 40 2.5610
5 KL1
C1P83 48.4 No No
Ca 19.9 (30/62)
Present study 114 92 1610
6 CAM 5.2 29 No No
(33/114)
NR: Not Reported.
Cytokeratin-positive cells in bone marrow of gastric cancer patients
G de Manzoni et al
1050
British Journal of Cancer (2002) 86(7), 1047–1051 ã 2002 Cancer Research UKFunke I, Fries S, Rolle M, Heiss MM, Untch M, Bohmert H, Schildberg FW,
Jauch KW (1996) Comparative analysis of bone marrow micrometastases
in breast and gastric cancer. Int J Cancer 65: 755–761
Funke I, Schraut W (1998) Meta-analyses of studies on bone marrow micro-
metastases: an independent prognostic impact remains to be substantiated.
J Clin Oncol 16: 557–566
Harbeck N, Uncht M, Pache L, Eiermann W (1994) Tumour cell detection in
the bone marrow of breast cancer patients at primary therapy: results of a
3-year median follow-up. Br J Cancer 69: 566–571
Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW, Schildberg FW
(1997) Clinical value of extended biologic staging by bone marrow micro-
metastases and tumor-associated proteases in gastric cancer. Ann Surg
226: 736–744; discussion 744–455
Hermanek P, Hutter RVP, Sobin LH, Wittekind C (1999) Classiﬁcation of
isolated tumor cells and micrometastasis. Cancer 86: 2668–2673
Jauch KW, Heiss MM, Gruetzner U, Funke I, Pantel K, Babic R, Eissner HJ,
Riethmueller G, Schildberg FW (1996) Prognostic signiﬁcance of bone
marrow micrometastases in patients with gastric cancer. J Clin Oncol 14:
1810–1817
Juhl H, Stritzel M, Wroblewski A, Henne-Bruns D, Kremer B, Schmiegel W,
Neumaier M, Wagener C, Schreiber H-W, Kalthoff H (1994) Iocytological
detection of micrometastatic cells: comparative evaluation of ﬁndings in
the peritoneal cavity and the bone marrow of gastric colorectal and
pancreatic cancer patients. Int J Cancer 57: 330–335
Kell MR, Winter DC, O’Sullivan GC, Shanahan F, Redmond HP (2000)
Biological behaviour and clinical implications of micrometastases. Br J
Surg 87: 1629–1639
Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G (1992) Prog-
nostic signiﬁcance of micrometastatic tumour cells in bone marrow of
colorectal cancer patients. Lancet 340: 685–689
Maehara Y, Yamamoto M, Oda S, Baba H, Kusumoto T, Ohno S, Ichiyoshi Y,
Sugimachi K (1996) Cytokeratin-positive cells in bone marrow for identi-
fying distant micrometastasis of gastric cancer. Br J Cancer 73: 83–87
O’Sullivan GC, Collins JK, O’Brien F, Crowley B, Murphy K, Lee G, Shana-
han F (1995) Micrometastases in bone marrow of patients undergoing
‘curative’ surgery for gastrointestinal cancer. Gastroenterology 109:
1535–1540
Page DL, Anderson TJ, Carter BA (1999) Minimal solid tumor involvement
of regional and distant sites. When is a metastasis not e metastasis? Cancer
86: 2589–2592
Pasini F, Pelosi G, Verlato G, Guidi G, Pavanel F, Tummarello D, Masotti A,
Cetto GL (1998) Positive immunostaining with MluC1 of bone marrow
aspirates predicts poor outcome in patients with small-cell lung cancer.
Ann Oncol 9: 181–185
Passlick B, Kubuschock B, Izbicki JR, Thetter O, Pantel K (1999) Isolated
tumor cells in bone marrow predict reduced survival in node-negative
non-small cell lung cancer. Ann Thorac Surg 68: 2053–2058
Pelosi G, Pasini F, Pavanel F, Bresaola E, Schiavon I, Iannucci A (1999a)
Effects of different immunolabeling techniques on the detection of small
cell lung cancer cells in bone marrow: a comparative study with clinical
correlations. J Histochem Cytochem 47: 1075–1088
Pelosi G, Pasini F, Ottensmeier C, Pavanel F, Bresaola E, Bonetti A, Fraggetta
A, Terzi A, Iannucci A, Cetto GL (1999b) Immunocytochemical assess-
ment of bone marrow aspirates for monitoring response to
chemotherapy in small-cell lung cancer patients. Br J Cancer 81: 1213–
1221
Schlimok G, Funke I, Pantel K, Strobel F, Lindemann F, Witte J, Riethmuller
G (1991) Micrometastatic tumor cells in bone marrow of patients with
gastric cancer: methodological aspects of detection and prognostic signiﬁ-
cance. Eur J Cancer 27: 1461–1465
Schott A, Vogel I, Krueger U, Kalthoff H, Schreiber HW, Schmiegel W,
Henne-Bruns D, Kremer B, Juhl H (1998) Isolated tumor cells are
frequently detectable in the peritoneal cavity of gastric and colorectal
cancer patients and serve as a new prognostic marker. Ann Surg 227:
372–379
Sobin LH, Wittekind C (1997) TNM Classiﬁcation of malignant tumours. 5th
edn New York: John Wiley & Sons
Thorban S, Roder JD, Nekarda H, Funk A, Pantel K, Siewert JR (1996) Disse-
minated epithelial tumor cells in bone marrow of patients with esophageal









Cytokeratin-positive cells in bone marrow of gastric cancer patients
G de Manzoni et al
1051
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(7), 1047–1051